| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $171.2M | -8.1% |
| SG&A Expense | $102.0M | +39.1% |
| Operating Income | -$273.2M | -5.2% |
| Interest Expense | $1.9M | +0.6% |
| Net Income | -$258.7M | -5.4% |
| EPS (Basic) | -$2.73 | +6.5% |
| EPS (Diluted) | -$2.73 | +6.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $163.6M | +192.7% |
| Short-term Investments | $208.7M | -34.2% |
| Current Assets | $378.2M | -0.0% |
| Total Assets | $527.7M | -6.8% |
| Current Liabilities | $40.7M | -16.1% |
| Total Liabilities | $64.5M | -12.6% |
| Stockholders' Equity | $463.2M | -6.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$209.7M | -7.6% |
| Capital Expenditures | $5.9M | -64.3% |
| Investing Cash Flow | $131.7M | +234.3% |
| Financing Cash Flow | $185.7M | -10.9% |
| Free Cash Flow | -$215.6M | -2.0% |